



**S3 Fig.** Progression-free survival (A) and overall survival (B) according to treatment arms in ERCC1 positive group. Progression-free survival (C) and overall survival (D) according to treatment arms in the ERCC1 negative group. ERCC1, excision repair cross-complementation group 1; GP, gemcitabine and cisplatin; IP, irinotecan and cisplatin.